Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial

Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684.

¹ Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland markku.laakso@kuh.fi.
² Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX.
³ Department of Medicine, Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland; and Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
⁴ Diabetes and Endocrinology Centre, Heart of England National Health Service Foundation Trust, and University of Birmingham, Birmingham, U.K.
⁵ Department of Medicine IV, Universitäts-Klinikum Tübingen, Tübingen, Germany.
⁶ Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
⁷ Boehringer Ingelheim Ky, Helsinki, Finland.
⁸ Boehringer Ingelheim Ltd., Bracknell, U.K.

No abstract available

Publication types